Selected article for: "low mortality risk and lymphocyte count"

Author: Fabio, Ciceri; Antonella, Castagna; Patrizia, Rovere-Querini; Francesco, De Cobelli; Annalisa, Ruggeri; Laura, Galli; Caterina, Conte; Rebecca, De Lorenzo; Andrea, Poli; Alberto, Ambrosio; Carlo, Signorelli; Eleonora, Bossi; Maria, Fazio; Cristina, Tresoldi; Sergio, Colombo; Giacomo, Monti; Efgeny, Fominskiy; Stefano, Franchini; Marzia, Spessot; Carlo, Martinenghi; Michele, Carlucci; Luigi, Beretta; Maria, Scandroglio Anna; Massimo, Clementi; Massimo, Locatelli; Moreno, Tresoldi; Paolo, Scarpellini; Gianvito, Martino; Emanuele, Bosi; Lorenzo, Dagna; Adriano, Lazzarin; Giovanni, Landoni; Alberto, Zangrillo
Title: Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy
  • Cord-id: svwtfshi
  • Document date: 2020_6_12
  • ID: svwtfshi
    Snippet: BACKGROUND: National health-system hospitals of Lombardy faced a heavy burden of admissions for acute respiratory distress syndromes associated with coronavirus disease (COVID-19). Data on patients of European origin affected by COVID-19 are limited. METHODS: All consecutive patients aged ≥18 years, coming from North-East of Milan's province and admitted at San Raffaele Hospital with COVID-19, between February 25th and March 24th, were reported, all patients were followed for at least one mont
    Document: BACKGROUND: National health-system hospitals of Lombardy faced a heavy burden of admissions for acute respiratory distress syndromes associated with coronavirus disease (COVID-19). Data on patients of European origin affected by COVID-19 are limited. METHODS: All consecutive patients aged ≥18 years, coming from North-East of Milan's province and admitted at San Raffaele Hospital with COVID-19, between February 25th and March 24th, were reported, all patients were followed for at least one month. Clinical and radiological features at admission and predictors of clinical outcomes were evaluated. RESULTS: Of the 500 patients admitted to the Emergency Unit, 410 patients were hospitalized and analyzed: median age was 65 (IQR 56–75) years, and the majority of patients were males (72.9%). Median (IQR) days from COVID-19 symptoms onset was 8 (5–11) days. At hospital admission, fever (≥ 37.5 °C) was present in 67.5% of patients. Median oxygen saturation (SpO2) was 93% (range 60–99), with median PaO(2)/FiO(2) ratio, 267 (IQR 184–314). Median Radiographic Assessment of Lung Edema (RALE) score was 9 (IQR 4–16). More than half of the patients (56.3%) had comorbidities, with hypertension, coronary heart disease, diabetes and chronic kidney failure being the most common. The probability of overall survival at day 28 was 66%. Multivariable analysis showed older age, coronary artery disease, cancer, low lymphocyte count and high RALE score as factors independently associated with an increased risk of mortality. CONCLUSION: In a large cohort of COVID-19 patients of European origin, main risk factors for mortality were older age, comorbidities, low lymphocyte count and high RALE.

    Search related documents:
    Co phrase search for related documents
    • adequate screening and lung involvement: 1
    • liver renal and lopinavir ritonavir: 1, 2, 3, 4, 5
    • liver renal and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • liver renal and lung involvement: 1, 2, 3
    • liver renal and lung involvement percentage: 1, 2
    • liver renal and lung opacity: 1, 2
    • liver renal and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • lombardy region and lopinavir ritonavir: 1, 2
    • lombardy region and lung involvement: 1
    • lopinavir ritonavir and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • lopinavir ritonavir and lung involvement: 1, 2, 3, 4, 5
    • lopinavir ritonavir and lung opacity: 1, 2
    • lopinavir ritonavir and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • lung disease and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • lung edema and lymphocyte count: 1, 2, 3
    • lung involvement and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
    • lung involvement percentage and lymphocyte count: 1, 2
    • lung opacity and lymphocyte count: 1, 2, 3, 4, 5, 6, 7